Vivimed Labs Limited (NSE:VIVIMEDLAB)
India · Delayed Price · Currency is INR 7.32
+0.30 (4.27%)
Jan 23, 2026, 3:29 PM IST
Vivimed Labs Revenue
Vivimed Labs had revenue of 208.24M INR in the quarter ending September 30, 2025, a decrease of -16.03%. This brings the company's revenue in the last twelve months to 1.09B, down -23.23% year-over-year. In the fiscal year ending March 31, 2025, Vivimed Labs had annual revenue of 1.21B, down -24.15%.
Revenue (ttm)
1.09B
Revenue Growth
-23.23%
P/S Ratio
0.53
Revenue / Employee
1.86M
Employees
586
Market Cap
582.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.21B | -384.07M | -24.15% |
| Mar 31, 2024 | 1.59B | -290.20M | -15.43% |
| Mar 31, 2023 | 1.88B | -504.90M | -21.16% |
| Mar 31, 2022 | 2.39B | -6.33B | -72.62% |
| Mar 31, 2021 | 8.71B | -1.96B | -18.35% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Ind-Swift Laboratories | 5.72B |
| Sigachi Industries | 5.09B |
| Sakar Healthcare | 2.04B |
| Valiant Laboratories | 1.86B |
| Bafna Pharmaceuticals | 1.42B |
| Vaishali Pharma | 1.17B |
| Alpa Laboratories | 1.11B |